BRPI0917315A2 - anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica - Google Patents

anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica

Info

Publication number: BRPI0917315A2
Authority: BR; Brazil
Prior art keywords: pharmaceutical composition; antibody; pharmaceutical; composition
Prior art date: 2008-11-07

Application number

BRPI0917315A

Other languages

English (en)

Inventor

Hangil Park

Kyung Jin Kim

Maximiliano Vasquez

Wei-Meng Zhao

Original Assignee

Galaxy Biotech Llc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-11-07

Filing date

2009-11-06

Publication date

2015-11-17

2009-11-06 Application filed by Galaxy Biotech Llc filed Critical Galaxy Biotech Llc

2015-11-17 Publication of BRPI0917315A2 publication Critical patent/BRPI0917315A2/pt

2020-12-08 Publication of BRPI0917315B1 publication Critical patent/BRPI0917315B1/pt

2021-05-25 Publication of BRPI0917315B8 publication Critical patent/BRPI0917315B8/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- G01N33/5759—
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Bioinformatics & Cheminformatics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Cell Biology (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Food Science & Technology (AREA)
Microbiology (AREA)
Hospice & Palliative Care (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)
Pathology (AREA)
Biotechnology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

BRPI0917315A 2008-11-07 2009-11-06 anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo BRPI0917315B8 (pt)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US11268608P	2008-11-07	2008-11-07
US61/112686		2008-11-07
US16487009P	2009-03-30	2009-03-30
US61/164870		2009-03-30
PCT/US2009/063647 WO2010054265A2 (en)	2008-11-07	2009-11-06	Monoclonal antibodies to fibroblast growth factor receptor 2

Publications (3)

Publication Number	Publication Date
BRPI0917315A2 true BRPI0917315A2 (pt)	2015-11-17
BRPI0917315B1 BRPI0917315B1 (pt)	2020-12-08
BRPI0917315B8 BRPI0917315B8 (pt)	2021-05-25

Family

ID=42153600

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0917315A BRPI0917315B8 (pt)	2008-11-07	2009-11-06	anticorpo monoclonal, seu uso e composição farmacêutica o compreendendo

Country Status (20)

Country	Link
US (8)	US8101723B2 (pt)
EP (4)	EP3290052B1 (pt)
JP (8)	JP5627591B2 (pt)
KR (1)	KR101699432B1 (pt)
CN (1)	CN102131524B (pt)
AU (1)	AU2009313357B2 (pt)
BR (1)	BRPI0917315B8 (pt)
CA (1)	CA2733668C (pt)
DK (3)	DK2365828T3 (pt)
ES (3)	ES2770134T3 (pt)
HR (2)	HRP20171640T1 (pt)
HU (1)	HUE035700T2 (pt)
LT (2)	LT3290052T (pt)
MX (1)	MX2011000455A (pt)
NO (1)	NO2842573T3 (pt)
PL (3)	PL2365828T3 (pt)
PT (3)	PT2365828E (pt)
RU (1)	RU2546254C9 (pt)
SI (2)	SI3290052T1 (pt)
WO (1)	WO2010054265A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9260525B2 (en)	2008-02-04	2016-02-16	Xiao-Jia Chang	Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
US20110059091A1 (en) *	2008-02-04	2011-03-10	Xiao-Jia Chang	Inhibitors of oncogenic isoforms and uses thereof
WO2012021841A2 (en) *	2010-08-12	2012-02-16	Attogen Inc.	Antibody molecules to oncogenic isoforms of fibroblast growth factor receptor-2 and uses thereof
LT3290052T (lt)	2008-11-07	2020-02-25	Galaxy Biotech, Llc	Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2
JP2013529076A (ja) *	2010-05-11	2013-07-18	アベオファーマシューティカルズ，インコーポレイテッド	抗ｆｇｆｒ２抗体
JP6400470B2 (ja)	2011-05-16	2018-10-03	ジェネロン（シャンハイ）コーポレイションリミテッド	多重特異性Ｆａｂ融合タンパク質および使用法
AR088941A1 (es) *	2011-11-23	2014-07-16	Bayer Ip Gmbh	Anticuerpos anti-fgfr2 y sus usos
KR20140114826A (ko)	2011-12-14	2014-09-29	시애틀 지네틱스, 인크.	Fgfr 항체 약물 콘주게이트 (adcs) 및 그의 용도
EP2822968B1 (en)	2012-03-08	2018-01-10	Janssen Vaccines & Prevention B.V.	Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
CA2870126C (en)	2012-04-09	2020-10-27	Daiichi Sankyo Company, Limited	Anti-fgfr2 antibody
WO2014089193A1 (en) *	2012-12-04	2014-06-12	Aveo Pharmaceuticals, Inc.	Anti-fgfr2 antibodies
CN104995512A (zh) *	2012-12-21	2015-10-21	詹森生物科技公司	用于可溶性成纤维细胞生长因子受体的灵敏的多重免疫测定
CN103145843B (zh) *	2013-02-20	2014-10-29	暨南大学	抗成纤维细胞生长因子受体的单链抗体
WO2014138364A2 (en)	2013-03-06	2014-09-12	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
NZ715201A (en) *	2013-08-01	2021-12-24	Five Prime Therapeutics Inc	Afucosylated anti-fgfr2iiib antibodies
WO2015053407A1 (ja) *	2013-10-08	2015-04-16	第一三共株式会社	抗ｆｇｆｒ２抗体と他剤の組合せ
CN103757026B (zh)	2013-12-20	2017-04-05	广州圣露生物技术有限公司	FGFR2b胞外段的基因序列、多肽及其应用
US20230190750A1 (en)	2014-06-13	2023-06-22	Genentech, Inc.	Methods of treating and preventing cancer drug resistance
CN104231079A (zh) *	2014-09-12	2014-12-24	暨南大学	一种靶向bFGF高亲和力受体结合位点的抗体及其应用
TW201642904A (zh) *	2015-04-08	2016-12-16	第一三共股份有限公司	含抗ｆｇｆｒ２抗體及其他藥劑之組成物
US10881734B2 (en)	2015-04-20	2021-01-05	Daiichi Sankyo Company, Limited	Monoclonal antibodies to human fibroblast growth factor receptor 2 (HFGFR2) and methods of use thereof
RU2638457C2 (ru) *	2015-09-28	2017-12-13	Общество С Ограниченной Ответственностью "Онкомакс"	Антитела, специфически связывающие рецептор 1 типа фактора роста фибробластов, применение антител для лечения онкологического заболевания, способ получения антител
EP3380523A1 (en) *	2015-11-23	2018-10-03	Five Prime Therapeutics, Inc.	Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
CA3017776A1 (en)	2016-03-15	2017-09-21	Generon (Shanghai) Corporation Ltd.	Multispecific fab fusion proteins and use thereof
US10093731B2 (en)	2017-02-24	2018-10-09	Kindred Biosciences, Inc.	Anti-IL31 antibodies for veterinary use
EP4650004A2 (en)	2017-05-16	2025-11-19	Five Prime Therapeutics, Inc.	Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
TWI811220B (zh)	2017-06-02	2023-08-11	比利時商艾伯林克斯公司	結合聚集蛋白聚糖之免疫球蛋白
AU2018354189A1 (en)	2017-10-24	2020-04-23	Crispr Therapeutics Ag	Compositions and methods for the depletion of CD117+ cells
AU2018355244B2 (en)	2017-10-24	2025-08-28	Crispr Therapeutics Ag	Compositions and methods for the depletion of CD117+ cells
WO2019084067A1 (en) *	2017-10-24	2019-05-02	Magenta Therapeutics, Inc.	ANTI-CD117 ANTIBODIES AND METHODS OF USE
CN112867735B (zh)	2018-09-07	2025-05-09	埃泰美德(香港)有限公司	双特异性抗原结合蛋白及其用途
AU2019355995A1 (en)	2018-10-05	2021-04-08	Five Prime Therapeutics, Inc.	Anti-FGFR2 antibody formulations
KR20220119143A (ko) *	2019-12-24	2022-08-26	디잘 (지앙수) 파마슈티칼 씨오., 리미티드	신규한 항fgfr2b 항체
JP7692419B2 (ja) *	2019-12-24	2025-06-13	ディザル（ジァンスー）ファーマシューティカル・カンパニー・リミテッド	新規抗ＦＧＦＲ２ｂ抗体
JP2023528454A (ja) *	2020-06-03	2023-07-04	ザ・ブロード・インスティテュート・インコーポレイテッド	線維芽細胞増殖因子受容体２に特異的に結合する二重パラトープアンタゴニスト抗体およびその使用方法
NZ797493A (en)	2020-10-22	2024-05-31	Regeneron Pharma	Anti-fgfr2 antibodies and methods of use thereof
WO2022143728A1 (zh) *	2020-12-29	2022-07-07	深圳福沃药业有限公司	抗fgfr2抗体及其用途
US20250277041A1 (en) *	2021-10-08	2025-09-04	Shenzhen Forward Pharmaceuticals Co., Limited	Anti-fgfr2 adcc enhanced antibody and use thereof
TW202342527A (zh)	2022-02-25	2023-11-01	美商安進公司	鱗狀非小細胞肺癌之治療
AU2023350283A1 (en) *	2022-09-30	2025-05-22	3H Pharmaceuticals Co., Ltd.	Anti-fgfr2b antibodies and uses thereof
CN118852431A (zh) *	2023-04-28	2024-10-29	武汉人福创新药物研发中心有限公司	抗FGFR2b单抗
CN118994393A (zh) *	2023-05-19	2024-11-22	广东东阳光药业股份有限公司	一种抗fgfr2抗体及其应用
CN119855835A (zh) *	2023-06-13	2025-04-18	南京维立志博生物科技股份有限公司	基于共同轻链产生双特异性抗体的方法
WO2025130905A1 (zh) *	2023-12-18	2025-06-26	山东先声生物制药有限公司	抗FGFR2b抗体-药物缀合物及其应用
WO2025218662A1 (zh) *	2024-04-16	2025-10-23	杭州中美华东制药有限公司	抗成纤维细胞生长因子受体2b的抗体及其用途
WO2025232811A1 (zh) *	2024-05-09	2025-11-13	正大天晴药业集团股份有限公司	靶向成纤维细胞生长因子受体2IIIb的抗体及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1988007089A1 (en)	1987-03-18	1988-09-22	Medical Research Council	Altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1991000916A2 (en) *	1989-07-06	1991-01-24	The Regents Of The University Of California	Receptors for fibroblast growth factors
DK0463151T3 (da)	1990-01-12	1996-07-01	Cell Genesys Inc	Frembringelse af xenogene antistoffer
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
US5863888A (en) *	1990-07-06	1999-01-26	Rhone-Poulenc Rorer Pharmaceuticals Inc.	Human Bek Fibroblast growth factor receptor
ATE185601T1 (de)	1990-07-10	1999-10-15	Cambridge Antibody Tech	Verfahren zur herstellung von spezifischen bindungspaargliedern
GB9015198D0 (en)	1990-07-10	1990-08-29	Brien Caroline J O	Binding substance
WO1993012227A1 (en)	1991-12-17	1993-06-24	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
US5639641A (en)	1992-09-09	1997-06-17	Immunogen Inc.	Resurfacing of rodent antibodies
US6066718A (en)	1992-09-25	2000-05-23	Novartis Corporation	Reshaped monoclonal antibodies against an immunoglobulin isotype
CA2174132A1 (en) *	1993-10-14	1995-04-20	Immunex Corporation	Fas antagonists and uses thereof
US5834597A (en)	1996-05-20	1998-11-10	Protein Design Labs, Inc.	Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
AU3494397A (en)	1996-06-18	1998-01-07	United States Of America, Represented By The Secretary, Department Of Health And Human Services, The	Fibroblast growth factor receptor activating gene i and related compositions and methods
US20030143676A1 (en)	1999-03-25	2003-07-31	Genesis Research And Development Corporation Limited	Fibroblast growth factor receptors and methods for their use
HK1045700B (zh) *	1999-04-28	2007-07-27	德克萨斯大学董事会	用於通过选择性抑制vegf来治疗癌症的组合物和方法
JP2001302699A (ja)	2000-04-17	2001-10-31	Nichirei Corp	ヒトｋｇｆｒに対する抗体
US20020115603A1 (en)	2000-06-22	2002-08-22	Chiron Corporation	Methods and compositions for the treatment of peripheral artery disease
CN100497389C (zh) *	2001-06-13	2009-06-10	根马布股份公司	表皮生长因子受体(egfr)的人单克隆抗体
AU2002329540A1 (en)	2001-06-20	2003-01-02	Morphosys Ag	Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
EP1539233B1 (en)	2001-07-12	2011-04-27	FOOTE, Jefferson	Super humanized antibodies
DK1469878T3 (da)	2002-01-31	2011-07-18	Max Planck Gesellschaft	FGFR agonister
KR100493460B1 (ko) *	2002-08-29	2005-06-07	재단법인서울대학교산학협력재단	암 세포에서 발현되는 ｆｇｆｒ2 이성체
US7220410B2 (en)	2003-04-18	2007-05-22	Galaxy Biotech, Llc	Monoclonal antibodies to hepatocyte growth factor
DK1648998T3 (en)	2003-07-18	2015-01-05	Amgen Inc	Specific binding agents for hepatocyte growth factor
WO2005066211A2 (en)	2003-12-19	2005-07-21	Five Prime Therapeutics, Inc.	Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
US7872016B2 (en) *	2004-05-25	2011-01-18	Yale University	Method for treating skeletal disorders resulting from FGFR malfunction
US7890267B2 (en)	2006-03-31	2011-02-15	Ordway Research Institute	Prognostic and diagnostic method for cancer therapy
AR059922A1 (es)	2006-04-01	2008-05-07	Galaxy Biotech Llc	Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
EP2018442A2 (en) *	2006-05-12	2009-01-28	Genentech, Inc.	Methods and compositions for the diagnosis and treatment of cancer
PT2027156E (pt)	2006-06-02	2011-04-18	Aveo Pharmaceuticals Inc	Proteínas de ligação ao factor de crescimento de hepatócito (hgf)
AU2007254853B2 (en)	2006-06-02	2011-11-17	Aveo Pharmaceuticals, Inc.	Hepatocyte growth factor (HGF) binding proteins
EP2046384A4 (en)	2006-06-15	2009-12-02	Fibron Ltd	ANTIBODIES BLOCKING FIBROBLAST GROWTH FACTOR RECEPTOR ACTIVATION AND METHODS OF USING THE SAME
AU2007305443B2 (en)	2006-09-29	2012-08-23	Oncomed Pharmaceuticals, Inc.	Compositions and methods for diagnosing and treating cancer
JP5570218B2 (ja) *	2006-11-03	2014-08-13	ユースリーファーマゲゼルシャフトミットベシュレンクテルハフツング	Ｆｇｆｒ４抗体
AU2008230880B2 (en) *	2007-03-23	2014-04-24	The Translational Genomics Research Institute	Method of diagnosing, classifying and treating endometrial cancer and precancer
EP2205277B1 (en)	2007-10-22	2017-07-26	Genmab A/S	Novel antibody therapies
US20110059091A1 (en)	2008-02-04	2011-03-10	Xiao-Jia Chang	Inhibitors of oncogenic isoforms and uses thereof
EP2177615A1 (en)	2008-10-10	2010-04-21	Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V.	Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
LT3290052T (lt)	2008-11-07	2020-02-25	Galaxy Biotech, Llc	Monokloniniai antikūnai fibroblastų augimo faktoriaus receptoriui 2
US20120301482A1 (en)	2009-08-25	2012-11-29	National Jewish Health	Methods and compositions for treatment of lung injury

2009
- 2009-11-06 LT LTEP17191118.3T patent/LT3290052T/lt unknown
- 2009-11-06 AU AU2009313357A patent/AU2009313357B2/en active Active
- 2009-11-06 PL PL09825523T patent/PL2365828T3/pl unknown
- 2009-11-06 ES ES17191118T patent/ES2770134T3/es active Active
- 2009-11-06 PL PL17191118T patent/PL3290052T3/pl unknown
- 2009-11-06 HU HUE14188785A patent/HUE035700T2/en unknown
- 2009-11-06 JP JP2011534932A patent/JP5627591B2/ja active Active
- 2009-11-06 ES ES14188785.1T patent/ES2646168T3/es active Active
- 2009-11-06 KR KR1020117002577A patent/KR101699432B1/ko active Active
- 2009-11-06 EP EP17191118.3A patent/EP3290052B1/en active Active
- 2009-11-06 PL PL14188785T patent/PL2842573T3/pl unknown
- 2009-11-06 PT PT98255235T patent/PT2365828E/pt unknown
- 2009-11-06 EP EP14188785.1A patent/EP2842573B1/en active Active
- 2009-11-06 PT PT171911183T patent/PT3290052T/pt unknown
- 2009-11-06 PT PT141887851T patent/PT2842573T/pt unknown
- 2009-11-06 EP EP19193727.5A patent/EP3783024A1/en active Pending
- 2009-11-06 NO NO14188785A patent/NO2842573T3/no unknown
- 2009-11-06 US US12/614,282 patent/US8101723B2/en active Active
- 2009-11-06 LT LTEP14188785.1T patent/LT2842573T/lt unknown
- 2009-11-06 DK DK09825523.5T patent/DK2365828T3/en active
- 2009-11-06 SI SI200932035T patent/SI3290052T1/sl unknown
- 2009-11-06 SI SI200931763T patent/SI2842573T1/en unknown
- 2009-11-06 CN CN200980132269.2A patent/CN102131524B/zh active Active
- 2009-11-06 DK DK14188785.1T patent/DK2842573T3/en active
- 2009-11-06 CA CA2733668A patent/CA2733668C/en active Active
- 2009-11-06 DK DK17191118.3T patent/DK3290052T3/da active
- 2009-11-06 EP EP09825523.5A patent/EP2365828B1/en active Active
- 2009-11-06 RU RU2011141890/10A patent/RU2546254C9/ru active
- 2009-11-06 ES ES09825523.5T patent/ES2523740T3/es active Active
- 2009-11-06 WO PCT/US2009/063647 patent/WO2010054265A2/en not_active Ceased
- 2009-11-06 BR BRPI0917315A patent/BRPI0917315B8/pt active IP Right Grant
- 2009-11-06 MX MX2011000455A patent/MX2011000455A/es active IP Right Grant
2011
- 2011-10-28 US US13/284,838 patent/US8603987B2/en active Active
2013
- 2013-11-04 US US14/071,520 patent/US9382324B2/en active Active
2014
- 2014-06-04 JP JP2014115617A patent/JP6342223B2/ja active Active
2016
- 2016-06-02 US US15/172,033 patent/US9834609B2/en active Active
- 2016-08-03 JP JP2016152670A patent/JP6445496B2/ja active Active
2017
- 2017-08-10 US US15/674,385 patent/US10138301B2/en active Active
- 2017-10-26 HR HRP20171640TT patent/HRP20171640T1/hr unknown
2018
- 2018-10-18 US US16/164,530 patent/US10689448B2/en active Active
- 2018-11-29 JP JP2018223183A patent/JP6661734B2/ja active Active
2020
- 2020-01-20 HR HRP20200090TT patent/HRP20200090T1/hr unknown
- 2020-02-06 JP JP2020018719A patent/JP6960485B2/ja active Active
- 2020-05-05 US US16/867,398 patent/US20200347141A1/en not_active Abandoned
2021
- 2021-10-11 JP JP2021166672A patent/JP7301106B2/ja active Active
2023
- 2023-03-10 US US18/182,242 patent/US20230242650A1/en active Pending
- 2023-06-20 JP JP2023100475A patent/JP2023116746A/ja active Pending
2024
- 2024-11-05 JP JP2024193584A patent/JP2025032085A/ja active Pending

Also Published As

Publication number	Publication date
JP6960485B2 (ja)	2021-11-05
US9382324B2 (en)	2016-07-05
US20200347141A1 (en)	2020-11-05
HK1249053A1 (en)	2018-10-26
NO2842573T3 (pt)	2018-02-24
ES2770134T3 (es)	2020-06-30
DK2842573T3 (en)	2017-10-30
CN102131524B (zh)	2014-05-14
PT3290052T (pt)	2020-02-06
JP7301106B2 (ja)	2023-06-30
CA2733668C (en)	2022-08-30
KR20110081141A (ko)	2011-07-13
AU2009313357B2 (en)	2015-06-11
US8603987B2 (en)	2013-12-10
HRP20171640T1 (hr)	2018-01-12
SI2842573T1 (en)	2018-01-31
HUE035700T2 (en)	2018-05-28
EP2365828A4 (en)	2012-06-06
US10138301B2 (en)	2018-11-27
PL2842573T3 (pl)	2018-04-30
EP2842573B1 (en)	2017-09-27
BRPI0917315B1 (pt)	2020-12-08
WO2010054265A2 (en)	2010-05-14
AU2009313357A1 (en)	2010-05-14
EP2365828A2 (en)	2011-09-21
PL3290052T3 (pl)	2020-06-29
JP2019052165A (ja)	2019-04-04
HK1160012A1 (en)	2012-08-10
US20100196364A1 (en)	2010-08-05
JP2025032085A (ja)	2025-03-11
JP6445496B2 (ja)	2018-12-26
JP5627591B2 (ja)	2014-11-19
ES2646168T3 (es)	2017-12-12
HK1207974A1 (en)	2016-02-19
US9834609B2 (en)	2017-12-05
US20160362496A1 (en)	2016-12-15
MX2011000455A (es)	2011-02-25
RU2546254C9 (ru)	2015-07-10
JP6661734B2 (ja)	2020-03-11
JP2020096615A (ja)	2020-06-25
BRPI0917315B8 (pt)	2021-05-25
EP3783024A1 (en)	2021-02-24
EP3290052A1 (en)	2018-03-07
JP2023116746A (ja)	2023-08-22
US20140193899A1 (en)	2014-07-10
RU2546254C2 (ru)	2015-04-10
US20230242650A1 (en)	2023-08-03
DK3290052T3 (da)	2020-02-03
JP2022008996A (ja)	2022-01-14
JP2012508184A (ja)	2012-04-05
LT2842573T (lt)	2017-12-11
LT3290052T (lt)	2020-02-25
PL2365828T3 (pl)	2015-04-30
DK2365828T3 (en)	2014-12-08
ES2523740T3 (es)	2014-12-01
CA3166399A1 (en)	2010-05-14
US8101723B2 (en)	2012-01-24
EP2365828B1 (en)	2014-10-15
US10689448B2 (en)	2020-06-23
US20180094063A1 (en)	2018-04-05
SI3290052T1 (sl)	2020-07-31
JP2014240385A (ja)	2014-12-25
EP2842573A1 (en)	2015-03-04
JP6342223B2 (ja)	2018-06-13
KR101699432B1 (ko)	2017-01-24
US20120134994A1 (en)	2012-05-31
US20190153105A1 (en)	2019-05-23
WO2010054265A3 (en)	2010-09-16
CA2733668A1 (en)	2010-05-14
PT2842573T (pt)	2017-12-04
RU2011141890A (ru)	2013-04-27
CN102131524A (zh)	2011-07-20
PT2365828E (pt)	2014-12-12
EP3290052B1 (en)	2019-12-25
JP2017019807A (ja)	2017-01-26
HRP20200090T1 (hr)	2020-04-03

Publication	Publication Date	Title
BRPI0917315A2 (pt)	2015-11-17	anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
BRPI0919942A2 (pt)	2014-12-23	Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt)	2017-05-23	composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt)	2015-12-29	composto, composição farmacêutica, e, uso de um composto
BRPI0917001A2 (pt)	2016-02-16	composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0908792A2 (pt)	2015-07-21	Composição, e, uso de uma combinação
BRPI0912717A2 (pt)	2014-12-23	Composição farmacêutica, e, uso de 5-azacitidina
BRPI0821115A2 (pt)	2015-06-16	Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0917579A2 (pt)	2016-10-11	composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0813770A2 (pt)	2014-12-30	Composição, e, uso de uma composição
BRPI1016219A2 (pt)	2016-04-26	composto, composição farmacêutica, e, uso de um composto
BRPI1008793A2 (pt)	2016-03-08	composto, uso de um composto, e, composição farmacêutica
BRPI1005322A2 (pt)	2019-09-24	anticorpo, composição farmacêutica e uso de pelo menos um anticorpo
BRPI0810696A2 (pt)	2014-10-21	Composto, composição farmacêutica, e, uso de um composto
BRPI0921879A2 (pt)	2018-10-16	composto, composição farmacêutica , e, uso de um composto
BRPI1010621A2 (pt)	2016-06-21	derivado de imidazoquinolinonas, sua composição farmacêutica e seu uso
BRPI1007018A2 (pt)	2016-03-29	composto, composição farmacêutica, e , uso de um composto.
BRPI1008906A2 (pt)	2016-03-15	composto, composição farmacêutica, e, uso de um composto.
BRPI1014316A2 (pt)	2016-04-05	composição, e, uso de uma composição
BR112012004335A2 (pt)	2015-09-08	composto, composição farmacêutica, e, uso do composto.
BRPI0914793A2 (pt)	2015-08-04	Composição, e, uso de uma composição
BRPI1008039A2 (pt)	2016-10-04	composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
BRPI0906937A2 (pt)	2016-04-19	composto, composição farmacêutica, e, uso de um composto
BRPI0906253A2 (pt)	2015-06-30	Composição de dentifrício, e, uso de uma composição
BRPI1006953A2 (pt)	2016-04-26	composição farmacêutica, e, uso de uma composição

Legal Events

Date	Code	Title	Description
2017-10-10	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2019-03-26	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]	Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI
2019-07-16	B07A	Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
2020-10-06	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2020-12-08	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/12/2020, OBSERVADAS AS CONDICOES LEGAIS.
2021-05-25	B16C	Correction of notification of the grant [chapter 16.3 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF